Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use. METHODS: In this double-blind, double-dummy study, we randomly assigned 5407 patients undergoing total hip replacement to receive apixaban at a dose of 2.5 mg orally twice daily or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication. RESULTS: A total of 1949 patients in the apixaban group (72.0%) and 1917 patients in the enoxaparin group (71.0%) could be evaluated for the primary efficacy analysis. The primary efficacy outcome occurred in 27 patients in the apixaban group (1.4%) and in 74 patients in the enoxaparin group (3.9%) (relative risk with apixaban, 0.36; 95% confidence interval [CI], 0.22 to 0.54; P<0.001 for both noninferiority and superiority; absolute risk reduction, 2.5 percentage points; 95% CI, 1.5 to 3.5). The composite outcome of major and clinically relevant nonmajor bleeding occurred in 129 of 2673 patients assigned to apixaban (4.8%) and 134 of 2659 assigned to enoxaparin (5.0%) (absolute difference in risk, -0.2 percentage points; 95% CI, -1.4 to 1.0). CONCLUSIONS: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00423319.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Cited by
Items 401–500 of 780
Sun, Z.-J., Zhao, Y., Qiu, G.-X., Wang, Y., Weng, X., Zhao, H., Shen, J., Jiang, Y., Li, Y., & Li, X. (2011) · Chinese Medical Sciences Journal · doi:10.1016/s1001-9294(12)60004-2 · Cited by 10
Ahuja, T., Raco, V., Papadopoulos, J., & Green, D. (2021) · PubMed · doi:10.1097/pts.0000000000000535 · Cited by 13
“Clopidogrel 75 mg daily 6 (20) NSAID 0 (0) Dual therapy 4 (13)”
BackgroundThe new oral anticoagulants: clinical use and reversal agent development
Costin, J. C., Ansell, J., Bakhru, S., Laulicht, B., & Steiner, S. S. (2015) · ISBT Science Series · doi:10.1111/voxs.12160 · Cited by 9
Joo, P. Y., Modrak, M., Park, N., Brand, J., Rubin, L. E., Grauer, J. N., & Bernstein, J. A. (2022) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-22-00228 · Cited by 9
Forbes, N., Yi, Q., Moayyedi, P., Bosch, J., Bhatt, D. L., Fox, K. A. A., & Eikelboom, J. W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18139 · Cited by 11
“24 27–30 In our study assessing GIB among patients with stable cardiovascular disease, we confirmed several of these risk factors, including increasing patient age, chronic kidney disease, liver disease, and hypertension.”
Nuevos anticoagulantes frente a anticoagulantes clásicos: ventajas e inconvenientes
García, J. P. (2013) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(13)74376-4 · Cited by 18
Alfarhan, M. F. A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010107 · Cited by 9
“(2006) [22] 0 27 0 18 24 2 Eriksson et al.”
BackgroundResultInfluentialYan, N. J., Song, F., Ouyang, Y., Li, D., Tian, H., Lin, Y., Linhardt, R. J., & Zhang, Z. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01579 · Cited by 9
Clinical Studies with Anticoagulants that Have Changed Clinical Practice
Hirsh, J., de Vries, T. A. C., Eikelboom, J. W., Bhagirath, V. C., & Chan, N. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760330 · Cited by 10
Kwong, L. M. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s26647 · Cited by 9
Rosencher, N., & Albaladejo, P. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.648614 · Cited by 10
“(started 12 h preoperatively) in reducing DVT, PE and all-cause death after TKR and THR, with no significant increase in major or clinically relevant bleeding [36,37].”
Prandoni, P., Temraz, S. N., & Taher, A. T. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.006 · Cited by 9
Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
Lessire, S., Dincq, A.-S., Douxfils, J., Devalet, B., Nicolas, J., Anne, S., Larock, A., Jean-Michel, D., Gourdin, M. J., & Mullier, F. (2014) · BioMed Research International · doi:10.1155/2014/616405 · Cited by 12
Thankappan, A., Strapps, W. R., DiPietro, M. A., Leander, K. R., Zhang, Z., Shin, M. K., Levorse, J. M., Desai, K., Xu, Y., Lai, K., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0505 · Cited by 9
Apixaban and oral implications
López-Galindo, M. P., & Sebastián, J. V. B. (2015) · Journal of Clinical and Experimental Dentistry · doi:10.4317/jced.52470 · Cited by 10
“Results Apixaban has been used for preventing thromboembolic events in acutely ill non-surgical patients (15) and following knee or hip replacement surgery (16,17), as well as in patients with acute coronary syndrome (ACS) (18) and in cases of atrial fibrillation (AF) (19,20).”
BackgroundBahloul, M., Regaieg, K., Chtara, K., Turki, O., Baccouch, N., Chaari, A., & Bouaziz, M. (2017) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2016.12.003 · Cited by 9
Vandermeulen, E., Decoster, J., Dewandre, P.-Y., Be, I., Vercauteren, M., & Verhamme, P. B. (2011) · PubMed · Cited by 13
Khatri, A., Machin, M., Vijay, A., Salim, S., Shalhoub, J., & Davies, A. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194294 · Cited by 10
Song, W., Ma, T., Cheng, Q.-Y., Wen, P., Wang, Q., Wu, J., Hao, L., Zhang, B., Wang, Q., & Zhang, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.837163 · Cited by 12
“Nine of the top 10 highly cited articles were RCTs with level I evidence, focusing on comparations between rivaroxaban (22–24, 28), dabigatran etexilat (25, 32), and apixaban (26, 27, 33) vs.”
BackgroundPerioperative Management of Anticoagulation—Review of Latest Evidence
Kannan, A., Poongkunran, C., Shenoy, S., & Abidov, A. A. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000121 · Cited by 9
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
Trkulja, V. (2016) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s74410 · Cited by 9
Trivedi, N. N., Fitzgerald, S. J., Schmaier, A. H., & Wera, G. D. (2019) · JBJS Reviews · doi:10.2106/jbjs.rvw.18.00010 · Cited by 10
Pharmacology and Safety of New Oral Anticoagulants
Levy, J. H. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.003 · Cited by 8
Statistical Fragility of Venous Thromboembolism Prophylaxis Following Total Joint Arthroplasty
Sequeira, S. B., Duvall, G. T., & Boucher, H. R. (2023) · Arthroplasty Today · doi:10.1016/j.artd.2023.101111 · Cited by 8
“Thirty-two RCTsmet all inclusion criteria andwere included in the statistical fragility analysis [2,11-35].”
BackgroundNew oral therapies for the prevention and treatment of venous thromboembolism
Hellwig, T. R., & Gulseth, M. P. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110601 · Cited by 8
King, D. A. L., Pow, R. E., Dickison, D., & Vale, P. R. (2016) · Internal Medicine Journal · doi:10.1111/imj.13139 · Cited by 8
The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2011
Patel, P. A., Ramakrishna, H., Andritsos, M. J., Wyckoff, T., Říha, H., & Augoustides, J. G. (2012) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2011.10.005 · Cited by 8
Ross, M. E., Glickman, A., Brennecke, A., Tayebnejad, A., & Guntupalli, S. R. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.505 · Cited by 8
Yong, B. S. J., Ling, R. R., Ramanathan, K. R., Fan, B. E., Li, R., Poh, J. W., Tan, C. S., Ho, S. W. L., Rochwerg, B. N., & Arya, R. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1787996 · Cited by 10
Wang, Z., Zheng, J., Zhao, Y., Xiang, Y., Chen, X., & Jin, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479840 · Cited by 8
Aryal, M. R., Pandit, A., Ghimire, S., Pathak, R., Karmacharya, P., Poudel, D. R., & Shamoun, F. E. (2015) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v5.27889 · Cited by 8
Latest developments in anticoagulant drug discovery
Broussalis, E., Anna, W., Trinka, E., Mutzenbach, J. S., & Killer‐Oberpfalzer, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.011 · Cited by 10
Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants
Gao, L., Tadrous, M., Knowles, S. R., Mamdani, M., Paterson, J. M., Juurlink, D. N., & Gomes, T. (2017) · Healthcare policy · doi:10.12927/hcpol.2017.25321 · Cited by 8
“They have also been shown to be superior for prophylaxis of deep vein thrombosis following hip or knee replacement surgeries (Eriksson et al. 2008; Lassen et al. 2010).”
BackgroundInfluentialDeitelzweig, S. B. (2012) · Hospital Practice · doi:10.3810/hp.2012.04.973 · Cited by 8
The Evolution of Oral Anticoagulant Therapy
Dittus, C. E., & Ansell, J. (2012) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.011 · Cited by 7
“5 mg twice daily, with enoxaparin, 40 mg daily, in THR patients.(20) This”
BackgroundUpdate on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients
Imbalzano, E., Orlando, L., Dattilo, G., Fazio, M. G. D., Camporese, G., Russo, V., Perrella, A., Bernardi, F. F., & Micco, P. D. (2024) · Medicina · doi:10.3390/medicina60010156 · Cited by 7
Salazar, C. A., Basilio-Flores, J. E., Málaga, G., Malasquez, G., & Bernardo, R. J. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011762.pub2 · Cited by 16
The role of novel anticoagulants in the management of venous thromboembolism
Skeik, N., Murphy, C. J., & Porten, B. R. (2014) · Vascular Medicine · doi:10.1177/1358863x14534309 · Cited by 7
Friedman, R. J. (2012) · PubMed · Cited by 7
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson, C. M., & Finks, S. W. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.048 · Cited by 7
Ueshima, S., Hira, D., Tomitsuka, C., Nomura, M., Kimura, Y., Yamane, T., Tabuchi, Y., Ozawa, T., Itoh, H., Horie, M., et al. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0353-7 · Cited by 7
Fan, K. L., Black, C. K., Abbate, O. A., Lu, K. B., Camden, R. C., & Evans, K. K. (2019) · Journal of Plastic Surgery and Hand Surgery · doi:10.1080/2000656x.2019.1650057 · Cited by 9
Polak, T. B., Cucchi, D. G. J., Darrow, J. J., & Versteegh, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058279 · Cited by 8
Liu, K. C., Bagrodia, N., Richardson, M. K., Piple, A. S., Kusnezov, N. A., Wang, J. C., Lieberman, J. R., & Heckmann, N. D. (2024) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-23-01213 · Cited by 7
Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
Beyer‐Westendorf, J., Werth, & Halbritter (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s24238 · Cited by 8
Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation
Gonzalo Eymin, L., & Jaffer, A. K. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0874-3 · Cited by 8
A systematic update on the state of novel anticoagulants and a primer on reversal and bridging
Knepper, J. P., Horne, D. C., Andrea, T., & Wakefield, T. W. (2013) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2013.04.006 · Cited by 7
Apixaban Versus Enoxaparin in Elective Major Orthopedic Surgery: A Clinical Review
Maniscalco, P., Caforio, M., Imberti, D., Porcellini, G., & Benedetti, R. (2014) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029614546328 · Cited by 8
“New oral anticoagulants (NOACs) have been developed to overcome these limitations and thereby improve patient care, especially after early hospital discharge and the need to manage the therapy by the patient himself.(3-12) Apixaban is an oral, direct, potent, and selective inhibitor of coagulation factor Xa (FXa) that…”
BackgroundAssessment of novel oral anticoagulant use within a community teaching hospital
Alghadeer, S. M., & Hornsby, L. B. (2016) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2016.02.002 · Cited by 8
“…dosing without monitoring, a lack of food interactions and fewer drug interactions (Connolly et al., 2009; Schulman et al., 2009; Patel et al., 2011; Turpie et al., 2011; Lopes et al., 2012; Bauersachs et al., 2010; Buller et al., 2012; Agnelli et al., 2013; Lassen et al., 2010a, 2010b).”
An update on the pharmaceutical management of thrombosis
Cosmi, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241233 · Cited by 8
Serrao, A., Lucani, B., Assanto, G. M., Fiori, L., Baldacci, E., Aprile, S. M., & Chistolini, A. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02070-2 · Cited by 7
Anticoagulant treatment: the end of the old agents?
Graf, L., & Tsakiris, D. A. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13684 · Cited by 7
Johnson, M. P. (2013) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0b013e31823776e6 · Cited by 7
“surgery in the phase 3 ADVANCE 2 and ADVANCE 3 (Apixaban Dose Orally Versus Anticoagulation With Enoxaparin-2 and -3) trials, respectively.(68,69) Apixaban was found to be more effective than enoxaparin in both trials, with a 9.”
BackgroundResultInamadar, A. C., Adya, K. A., & Palit, A. (2016) · Indian Journal of Dermatology Venereology and Leprology · doi:10.4103/0378-6323.184199 · Cited by 9
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
Mezue, K. N., Obiagwu, C., John, J., Sharma, A., Yang, F., & Shani, J. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160720092024 · Cited by 9
Yang, T., Murillo, M. U., Vadhariya, A., Wilson, A., Putney, D. R., & Muntz, J. E. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxy080 · Cited by 7
Hong, K. (2019) · Journal of Stroke · doi:10.5853/jos.2019.01970 · Cited by 7
“When compared to exoxaparin 40 mg OD, apixaban was more effective for preventing total VTE or all-cause death without a significant increase in the risk of major or CRNM bleeding.(57,58) In two trials (Studying Thrombosis After Replacement Surgery [STARS] E-3 [n=716] and STARS J-V [n=610]) enrolling East Asian patient…”
BackgroundSchmidt, K., Krüger, K., Langer, E., Schmutzler, M., Johnen, E., Wernecke, K. D., von Heymann, C., & Körber, M. K. (2019) · Blood transfusion · doi:10.2450/2018.0028-18 · Cited by 9
Li, H., Farajtabar, A., Xie, Y., Li, Z., & Zhao, H. (2020) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2020.106200 · Cited by 7
Deep Vein Thrombosis and Pulmonary Embolism
Goldhaber, S. Z. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00016-6 · Cited by 8
Is Patent Foramen Ovale a Risk Factor for Perioperative Stroke?
Kasner, S. E., & Messe, S. R. (2018) · JAMA · doi:10.1001/jama.2017.21902 · Cited by 7
Kumar, P., Mediwake, R., & Rhead, C. (2020) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0210 · Cited by 8
Cancer-associated thrombosis: an update
Shelke, A. R., & Khorana, A. A. (2011) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2012.02.001 · Cited by 6
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty
Aikens, G. B. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i3.188 · Cited by 6
Novel oral anticoagulants in atrial fibrillation: will the benefit outweigh the cost?
Goudevenos, J. A., Pipilis, A. G., & Vardas, P. E. (2012) · PubMed · Cited by 7
Profilaxis tromboembólica en cirugía ortopédica y traumatología
Gutiérrez-Guisado, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.04.016 · Cited by 6
Aspirin thromboprophylaxis in joint replacement surgery
Sharda, A. V., Fatovic, K., & Bauer, K. A. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12649 · Cited by 6
Bell, S., Orellana, T. J., Garrett, A. A., Smith, K. J., Kim, H., Rosiello, A., Rush, S. K., Berger, J. L., & Lesnock, J. L. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004922 · Cited by 6
“30 31 32 While these findings occurred in orthopedic patients without malignancy, it may be useful to consider further research into aspirin for VTE prophylaxis in post-operative gynecologic oncology patients.”
BackgroundArrayás, I. G., Fernández, C. S., Cerezo, J. F. G., Nicolás, L. B., de Salas-Cansado, M., & Rubio‐Terres, C. (2012) · PubMed · doi:10.4321/s1135-57272012000600006 · Cited by 6
Frost, C. E., Nepal, S., Byon, W., Moore, K. T., Reeves, R. A., Boyd, R. A., & LaCreta, F. P. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.447 · Cited by 6
Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?
Dobesh, P. P., & Terry, K. J. (2013) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-013-0029-z · Cited by 6
Novel drugs for oral anticoagulation pharmacotherapy
Capodanno, D., Giacchi, G., & Tamburino, C. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.18 · Cited by 6
Perioperative Approach to Anticoagulants and Hematologic Disorders
Kim, J., Huh, R., & Jaffer, A. K. (2016) · Anesthesiology Clinics · doi:10.1016/j.anclin.2015.10.010 · Cited by 6
Anticoagulants: dose control methods and inhibitors
Bitsadze, V. O., Викторовна, С. Е., Khizroeva, J. K., Tretyakova, M. V., Tsibizova, V. I., Gashimova, N. R., Nakaidze, I. A., Elalamy, I., Gris, J., & Makatsariya, A. D. (2022) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2022.293 · Cited by 7
The place of new oral anticoagulants in travel medicine
Ringwald, J., Grauer, M., Eckstein, R., & Jelínek, T. (2013) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2013.11.005 · Cited by 8
Mahan, C. E., & Kaatz, S. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1133 · Cited by 6
Shoda, N., Yasunaga, H., Horiguchi, H., Fushimi, K., Matsuda, S., Kadono, Y., & Tanaka, S. (2014) · Modern Rheumatology · doi:10.3109/14397595.2014.997424 · Cited by 7
Contemporary Anticoagulation Reversal
Mancl, E. E., Crawford, A. N., & Voils, S. A. (2012) · Journal of Pharmacy Practice · doi:10.1177/0897190012465989 · Cited by 6
Improving prevention and treatment of venous thromboembolism: clinical trial results
Mahan, C. E., & Spyropoulos, A. C. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.667026 · Cited by 6
Denas, G., & Pengo, V. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.668524 · Cited by 6
“3 Apixaban The ADVANCE program [74-76] was designed to assess the efficacy and safety of apixaban for the prevention of thromboembolism after major orthopedic surgery.”
BackgroundUpdate on Anticoagulation: What the Interventional Radiologist Needs to Know
Kamath, S. D., & McMahon, B. J. (2016) · Seminars in Interventional Radiology · doi:10.1055/s-0036-1582124 · Cited by 6
Yan, X., Gu, X., Zhou, L., Lin, H., & Wu, B. Y. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0444-5 · Cited by 6
“Our analysis suggests that based on inputs mainly from the ADVANCE-2 clinical trial and current direct medical costs in the Chinese setting, Chinese patients in a cohort population who receive apixaban for prophylaxis following TKR would gain more health benefits but incur higher overall costs for up to 5 years than w…”
BackgroundMethodInfluentialPostorthopedic Surgery Joint Replacement Surgery Venous Thromboembolism Prophylaxis
Kwong, L. M., & Kimball, J. A. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.001 · Cited by 6
Вавилова, Т. В. (2019) · Kardiologiia · doi:10.18087/cardio.n951 · Cited by 6
“Показано, что анти-Ха активность плазмы на фоне стартового приема прямых ингибиторов фактора Ха сопоставима с кривой ее нарастания при введении эноксапарина в лечебной дозе и для ривароксабана, и для апиксабана [12, 13].”
Hoffmann, C., Leven, C., Mao, R. L., MOREUIL, C. D., & Lacut, K. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.05.026 · Cited by 9
Rooney, T. P., Barrack, R. L., Clohisy, J. C. F., Nunley, R. M., & Lawrie, C. M. (2021) · The Journal of Arthroplasty · doi:10.1016/j.arth.2021.03.030 · Cited by 6
Oral factor Xa inhibitors for the long-term management of ACS
Wisler, J. W., & Becker, R. C. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.18 · Cited by 9
Rivaroxaban for the prevention and treatment of venous thromboembolism
Turpie, A. G. G. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00980.x · Cited by 6
Momeni, A., Yesantharao, P. S., Meyer, S., Posternak, V., Shefren, K., Przybylo, V., Januszyk, M., & Pannucci, C. J. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012168 · Cited by 6
Zhou, W., Bozenhardt, E., Alexander, G. E., Zierhut, M. L., Merali, S. J., Ajavon‐Hartmann, A., Zannikos, P., Back, H., Suh, E., Goyal, N., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70037 · Cited by 6
Neck‐vein thrombosis during spaceflight
Limper, U., & Jordan, J. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70300 · Cited by 6
“75,76 Due to an increased risk for trauma during extravehicular activities and high impact forces during return to Earth, it has been suggested to stop prophylaxis in a timely manner.”
Baud, J.-M., Matrand, G., Georges, J., Beaufils, P., & Livarek, B. (2011) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2011.10.003 · Cited by 5
[New anticoagulants: dabigatran, rivaroxaban and apixaban].
Ruiz, Á. G. V., López, A. N. R., & Viramontes, M. E. M. (2012) · PubMed · Cited by 9
Total Joint Arthroplasty in Patients With Atrial Septal Defects: What Are the 90-Day Complications?
Bido, J., Puri, S., Salvati, E. A., Cross, M. B., Valle, A. G. D., & Gausden, E. B. (2022) · Arthroplasty Today · doi:10.1016/j.artd.2022.07.005 · Cited by 5
“The rate of bleeding complications was approximately 5% in both groups [13], highlighting the increased risk of bleeding with potent anticoagulants.”
BackgroundHu, Z., Persaud, Y., & Ahuja, S. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104347 · Cited by 6
Apixaban plasma concentrations in patients with obesity
Al-Aieshy, F., Skeppholm, M., Fyrestam, J., Johansson, F., Pohanka, A., & Malmström, R. E. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03696-4 · Cited by 5
“A pooled analysis of ADVANCE 2 and 3 showed no difference in either safety or efficacy for patients with BMI ≥ 30 kg/m 2 treated with apixaban compared to enoxaparin in the prevention of VTE after orthopedic surgery [20–22].”
MethodDiethylzinc Amylates: Selective Iodine–Zinc Exchange Reagents at Room Temperature
Trauner, F., Boutet, B., Rambaud, F., Ngo, V. N., & Didier, D. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c01924 · Cited by 5
Prevention of Venous Thromboembolism in Patients with Hemorrhagic Stroke
Chaudhry, F. S., Schneck, M. J., Morales‐Vidal, S., Javaid, F., & Ruland, S. D. (2013) · Topics in Stroke Rehabilitation · doi:10.1310/tscir2001-108 · Cited by 5
Zapata, L. V., Malone, D. C., & Ross, D. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1445-2 · Cited by 5
“Despite prophylaxis and current treatments, sub-clinical DVT develops in about 15–20 % of patients soon after hip surgery and in 30–40 % of those who undergo knee replacement, while symptomatic VTE occurs in 2–4 % during the first 3 months post-surgery [6, 7].”
BackgroundConventional and New Oral Anticoagulants in the Treatment of Chest Disease and its Complications
Gallego, P., Roldán, V., & Lip, G. Y. H. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201301-0141pp · Cited by 5
Metadata
- Authors
- Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M.
- Affiliations
- University of Copenhagen (DK)
- South Australia Pathology (AU)
- University of Oklahoma Health Sciences Center (US)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133686162
- Cited by
- 775
- References
- 35
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 32 · 2023: 18 · 2022: 25 · 2021: 33 · 2020: 34 · 2019: 39 · 2018: 41 · 2017: 39 · 2016: 62 · 2015: 66 · 2014: 67 · 2013: 121 · 2012: 102
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, factor Xa inhibitors, low molecular weight heparin, deep vein thrombosis, pulmonary embolism, bleeding risk, venography, non-inferiority, postoperative thromboprophylaxis, oral anticoagulants, venous thromboembolism
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Confidence Intervals, Treatment Outcome, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Young Adult, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.